Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.
You may also be interested in...
Bayer/Onyx Nexavar Hits Sales Plateau After Rapid Initial Uptake
Aggressive clinical trial plan aims to add new indications, build Nexavar oncology franchise on kidney cancer success.
Bayer/Onyx Nexavar Hits Sales Plateau After Rapid Initial Uptake
Aggressive clinical trial plan aims to add new indications, build Nexavar oncology franchise on kidney cancer success.
Wyeth CCI-779 Survival Benefit Over Interferon In Kidney Cancer May Warrant First-Line Use
CCI-779 (temsirolimus) monotherapy is associated with a 49% improvement in median overall survival compared to interferon in advanced renal cell carcinoma patients.